”I’m pleased that we once again secure a high subscription rate in a challenging market. The outcome is evidence that not only our institutional and other major shareholders as well as key individuals in management participated, but also that a large number of smaller investors decided to subscribe. Our shareholders have once again demonstrated their strong support for our commercialization plan which we now can pursue with undeterred force,” comments Per Andersson, CEO of
In connection to the rights issue completed in
”We feel confident in continuing on our chosen path, strengthened by the knowledge that we now have necessary funds to successfully finance our operations until launch. The budgeted cost ahead of the launch has also been reduced, partly by determining the launch date and partly by the fact that we no longer need to allocate funds for a legal dispute,” comments Per Andersson.
The proceeds raised by the exercise of warrants of series TO5 will primarily be used to fund pre-launch activities for Dasynoc on the US market as well as general operation purposes, ongoing operational costs and continued development of product candidates.
For further information, please contact:
Finance Director
Mob: +46 (0) 708365617
E-mail: niklas.baeckstrom@xspray.com
About
Xspray Pharma’s shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com
© Modular Finance, source